Gene Therapy for Hemophilia

Gene therapy has remained a constant prospect in the sphere of hemophilia treatment. For over two decades and the question remained: Is this just a dream, or could it one day become a reality?Hemophilia gene therapy has finally been approved. David Page talks to hemophilia specialists that will dive deep into understanding how the treatment works, its significance in advancing treatment, and how a one time treatment could change a severe condition to a milder one.Though not a definitive cure, gene therapy for hemophilia has transformed the dream of a cure into a reality for the future.David and his guests will provide exclusive insights into one of the most significant medical breakthroughs of our era.

Recent Episodes

View all

April 13, 2026

All About Von Willebrand Disease: Von Willebrand Disease 101

2026 marks the 100th year anniversary of when Dr Eric Von Willebrand first described the condition in a five year old girl. With this anniversary, we at the Canadian Hemophilia Society feel it's the perfect time to focus on increasing awareness, improving diagnosis, and addressing the fact that VWD remains under diagnosed and/or misdiagnosed. With that in mind, we're joined in this first episode by Dr. Dawn Goodyear, clinical associate professor and co-director of the southern Alberta rare blood

Listen to the Episode

Feb. 11, 2026

Shared Decision-Making

Over the last several years, gene therapy for hemophilia B has become a reality. Some received it through clinical trials, and others received it after marketing authorizations and reimbursement approvals in their countries. Each of them had a difficult, life-changing decision to make. They needed to fully understand the potential benefits and risks, and the physicians responsible for their treatment needed to be assured that they were providing fully informed consent to the therapy. This proces

Listen to the Episode

Feb. 10, 2026

Four People Describe Their Experiences with Hemophilia B Gene Therapy

Over the last several years, gene therapy for hemophilia B has become a reality. Some received it through clinical trials. Others received it after marketing authorizations and reimbursement approvals in their countries. In this episode of our second podcast series, GENE THERAPY FOR HEMOPHILIA – FROM DREAM TO REALITY, four of these people were asked “Are you happy you made the decision to receive gene therapy? Why or why not?” Host: David Page, Canadian Hemophilia Society Guest Speakers: D

Listen to the Episode

Jan. 28, 2026

If Gene Therapy for Hemophilia B Were Available Tomorrow, Would You Want to Receive It?

For the last 40 years, we have witnessed tremendous advances in care and treatment for people with hemophilia. Gene therapy has been a dream for most of those 40 years, and the last two to three years, two gene therapies for hemophilia B have been approved by regulatory bodies. But are they for everybody? In this episode of our second podcast series, GENE THERAPY FOR HEMOPHILIA – FROM DREAM TO REALITY, we will ask four people with severe hemophilia B to answer this question, “If gene therapy for

Listen to the Episode

Jan. 28, 2026

Overview of Gene Therapy Approaches

In this first episode of our second podcast series, GENE THERAPY FOR HEMOPHILIA – FROM DREAM TO REALITY, Dr. David Lillicrap describes what gene therapy is in 2026 and hopefully how it works. Dr. Lillicrap is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Ontario, and chair in Canadian Molecular Hemostasis Research. Host: Brian O’Mahony, Chief Executive, Irish Haemophilia Society Guest Speakers: James Foley, Ireland; Brian O'Laughlin, Irel

Listen to the Episode

Feb. 19, 2025

WEBINAR 2: [FR] Un Pas en Arrière, Deux Pas en Avant

Le webinaire de la Société canadienne de l'hémophilie a abordé la thérapie génique pour les hémophiles. Dr. Jean St. Louis a expliqué les différences entre les injections de facteurs et la thérapie génique, en utilisant des vecteurs AAV pour introduire des gènes dans les cellules du foie. Il a détaillé les thérapies géniques approuvées par Santé Canada : MGX et Bec Vibes, soulignant leurs différences de dose et de taux d'échec. Les données à long terme montrent une réduction significative des sa

Listen to the Episode

View all Episodes